# US 2024/0189293 A1 · Compositions And Methods For Treating Gulf War Illness

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189293 A1
- Document ID: US20240189293A1
- Status: Published application
- Kind: A1
- Application number: 18/347,811
- Filed: 2023-07-06
- Published: 2024-06-13
- Earliest claimed: 2022-07-06
- Applicants: The United States Government As Represented By The Department of Veterans Affairs
- Inventors: Bruce Citron
- Web page: https://patentgrep.com/patent/US20240189293A1

## CPC

- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 31/26: Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
- A61K 31/426: 1,3-Thiazoles
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosure relates to compositions and methods of treating Gulf War illness or syndrome in a subject. The method comprises administering to a subject in need of treatment an effective amount of a nuclear receptor peroxisome proliferator-activated receptor gamma agonist and a nuclear factor erythroid 2-related factor 2 agonist.

## Claims

### Claim 1

A method of treating of Gulf War illness or syndrome in a subject, the method comprising: administering to the subject in need thereof a therapeutically effective amount of a nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a nuclear factor erythroid 2-related factor 2 (Nrf2) agonist.

### Claim 2 (depends on 1)

The method of claim 1, wherein the PPAR-γ agonist is pioglitazone or rosiglitazone.

### Claim 3 (depends on 1)

The method of claim 1, wherein the Nrf2 agonist is tert-butylhydroquinone (t-BHQ) or sulforaphane.

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6 (depends on 2)

The method of claim 2, wherein the pioglitazone is administered orally, subcutaneously or intraperitoneally.

### Claim 7 (depends on 3)

The method of claim 3, wherein the t-HBQ is administered orally, subcutaneously or intraperitoneally.

### Claim 8 (depends on 2)

The method of claim 2, wherein the therapeutically effective amount of pioglitazone is 0.1 mg to 0.4 mg/kg body weight per day.

### Claim 9 (depends on 3)

The method of claim 3, wherein the therapeutically effective amount of t-BHQ is 1.0 mg to 5.0 mg/kg body weight per day.

### Claim 10 (depends on 1)

The method of claim 1, further comprising administering a therapeutically effective amount of one or more transcription factor modulators.

### Claim 11 (depends on 3)

The method of claim 3, wherein the administration of pioglitazone and t-BHQ reduces or ameliorates one or more symptoms of Gulf War illness or syndrome.

### Claim 12 (depends on 11)

The method of claim 11, wherein the one or more symptoms of Gulf War illness or syndrome is fatigue, musculoskeletal pain, skin rashes, diarrhea, headache, memory loss, spatial memory deficits, sleep disturbances or a combination thereof.

### Claim 13 (depends on 1)

The method of claim 1, wherein the administration of PPAR-γ) agonist and a nuclear factor erythroid 2-related factor 2 (Nrf2) agonist increases stamina, improve cognition, improve information seeking or a combination thereof in the subject.

### Claim 14

A method of ameliorating one or more symptoms of ameliorating one or more symptoms of Gulf War illness or syndrome in a subject, the method comprising: administering to the subject in need thereof a therapeutically effective amount of a nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a nuclear factor erythroid 2-related factor 2 (Nrf2) agonist.

### Claim 15

A method of inhibiting neurodegeneration or effecting neuroprotection in a subject in need thereof, the method comprising: administering to the subject in need thereof a therapeutically effective amount of a nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a nuclear factor erythroid 2-related factor 2 (Nrf2) agonist.

### Claim 16 (depends on 15)

The method of claim 15, wherein the neurodegeneration or neuroprotection is associated with Alzheimer's disease, Parkinson's disease, traumatic brain injury, amyotrophic lateral sclerosis, ischemic stroke or a combination thereof.

### Claim 17 (depends on 14)

The method of claim 14, wherein the PPAR-γ agonist is pioglitazone.

### Claim 18 (depends on 14)

The method of claim 14, wherein the Nrf2 agonist is tert-butylhydroquinone (t-BHQ).

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21 (depends on 17)

The method of claim 17, wherein the pioglitazone is administered orally.

### Claim 22 (depends on 18)

The method of claim 18, wherein the t-HBQ is administered orally.

### Claim 23 (depends on 17)

The method of claim 17, wherein the therapeutically effective amount of pioglitazone is 0.1 mg to 0.4 mg/kg body weight per day.

### Claim 24 (depends on 18)

The method of claim 18, wherein the therapeutically effective amount of t-BHQ is 1.0 mg to 5.0 mg/kg body weight per day.

### Claim at position 25

-31. (canceled)
